Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Retina Consultants of Houston
mi
from
Houston, TX
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Retina Consultants of Houston
mi
from
Houston, TX
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Retinal Consultants of San Antonio
mi
from
San Antonio, TX
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Retinal Consultants of San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Arizona Retina and Vitreous Consultants
mi
from
Phoenix, AZ
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Arizona Retina and Vitreous Consultants
mi
from
Phoenix, AZ
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Macula and Retina Institute
mi
from
Glendale, CA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Macula and Retina Institute
mi
from
Glendale, CA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
South Coast Retina Center
mi
from
Long Beach, CA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
South Coast Retina Center
mi
from
Long Beach, CA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Retina Macula Specialists of Miami
mi
from
Miami, FL
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Retina Macula Specialists of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Florida Retina Institute
mi
from
Orlando, FL
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Florida Retina Institute
mi
from
Orlando, FL
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Illinois Retina Associates, SC
mi
from
Oak Park, IL
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Illinois Retina Associates, SC
mi
from
Oak Park, IL
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Retina Associates, PA
mi
from
Shawnee Mission, KA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Retina Associates, PA
mi
from
Shawnee Mission, KA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Ophthalmic Consultants of Boston
mi
from
Boston, MA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Ophthalmic Consultants of Boston
mi
from
Boston, MA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Retina Associates of Western New York
mi
from
Rochester, NY
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Retina Associates of Western New York
mi
from
Rochester, NY
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Retina-Vitreous Surgeons of Central New York, PC
mi
from
Syracuse, NY
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Retina-Vitreous Surgeons of Central New York, PC
mi
from
Syracuse, NY
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Western Carolina Clinical Research, LLC
mi
from
Asheville, NC
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Western Carolina Clinical Research, LLC
mi
from
Asheville, NC
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Retina Vitreous Consultants
mi
from
Monroeville, PA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Retina Vitreous Consultants
mi
from
Monroeville, PA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Southeastern Retina Associates
mi
from
Chattanooga, TN
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Southeastern Retina Associates
mi
from
Chattanooga, TN
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Emory Eye Center
mi
from
Atlanta, GA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Emory Eye Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Northwestern Medical Faculty Foundation
mi
from
Chicago, IL
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Northwestern Medical Faculty Foundation
mi
from
Chicago, IL
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Eye Associates of Northeast Louisiana dba Haik Humble Eye Center
mi
from
West Monroe, LA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Eye Associates of Northeast Louisiana dba Haik Humble Eye Center
mi
from
West Monroe, LA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Kellogg Eye Center at University of Michigan
mi
from
Ann Arbor, MI
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Kellogg Eye Center at University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System, Dept of Ophthalmology and Eye Care Services
mi
from
Detroit, MI
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System, Dept of Ophthalmology and Eye Care Services
mi
from
Detroit, MI
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
The Retina Center
mi
from
Minneapolis, MN
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
The Retina Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Eye Associates of New Mexico
mi
from
Albuquerque, NM
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Eye Associates of New Mexico
mi
from
Albuquerque, NM
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
MaculaCare
mi
from
New York, NY
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
MaculaCare
mi
from
New York, NY
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Kittner Eye Center
mi
from
Chapel Hill, NC
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Kittner Eye Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Dean A. McGee Eye Institute
mi
from
Oklahoma City, OK
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Dean A. McGee Eye Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Robert E. Torti, MD, PA dba Retina Specialists
mi
from
DeSoto, TX
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Robert E. Torti, MD, PA dba Retina Specialists
mi
from
DeSoto, TX
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Baylor Eye Physicians and Surgeons
mi
from
Houston, TX
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Baylor Eye Physicians and Surgeons
mi
from
Houston, TX
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Valley Retina Institute, P.A.
mi
from
McAllen, TX
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Valley Retina Institute, P.A.
mi
from
McAllen, TX
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Medical Center Ophthalmology Associates
mi
from
San Antonio, TX
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Medical Center Ophthalmology Associates
mi
from
San Antonio, TX
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Retina Institute of Virginia
mi
from
Richmond, VA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Retina Institute of Virginia
mi
from
Richmond, VA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Loma Linda University Health Care, Department of Ophthalmology
mi
from
Loma Linda, CA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Loma Linda University Health Care, Department of Ophthalmology
mi
from
Loma Linda, CA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
University of Florida College of Med., Department of Ophthalmology, Jacksonville Health Science Cent
mi
from
Jacksonville, FL
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
University of Florida College of Med., Department of Ophthalmology, Jacksonville Health Science Cent
mi
from
Jacksonville, FL
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
University of Illinois at Chicago Medical Center
mi
from
Chicago, IL
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
University of Illinois at Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
NorthShore University HealthSystem
mi
from
Glenview, IL
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
NorthShore University HealthSystem
mi
from
Glenview, IL
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Wilmer Eye Institute at Johns Hopkins
mi
from
Baltimore, MD
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Wilmer Eye Institute at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Valley Retina Institute
mi
from
DeSoto, TX
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Valley Retina Institute
mi
from
DeSoto, TX
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin-Madison, Dept of Ophthalmology/Retina Service
mi
from
Madison, WI
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin-Madison, Dept of Ophthalmology/Retina Service
mi
from
Madison, WI
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
UBC/VCHA Eye Care Centre
mi
from
Vancouver,
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
UBC/VCHA Eye Care Centre
mi
from
Vancouver,
Click here to add this to my saved trials
Effect of Dairy Consumption on Glycemic Control, Body Weight and Cardiovascular Risk in Patients With Type 2 Diabetes
Effect of Consumption of Dairy Products on Glycemic Control, Body Weight and Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Randomized Controlled Clinical Study
Status: Enrolling
Updated:  12/31/1969
Joslin Diabetes Center
mi
from
Boston, MA
Effect of Dairy Consumption on Glycemic Control, Body Weight and Cardiovascular Risk in Patients With Type 2 Diabetes
Effect of Consumption of Dairy Products on Glycemic Control, Body Weight and Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Randomized Controlled Clinical Study
Status: Enrolling
Updated: 12/31/1969
Joslin Diabetes Center
mi
from
Boston, MA
Click here to add this to my saved trials
Effect of Dairy Consumption on Glycemic Control, Body Weight and Cardiovascular Risk Factors
The Effect of Dairy Product Consumption on Glycemic Control, Body Weight and Cardiovascular Risk Factors in Patients Enrolled in the Joslin Weight Achievement and Intensive Treatment (Why WAIT) Program: A Prospective Cohort Study
Status: Enrolling
Updated:  12/31/1969
Joslin Diabetes Center
mi
from
Boston, MA
Effect of Dairy Consumption on Glycemic Control, Body Weight and Cardiovascular Risk Factors
The Effect of Dairy Product Consumption on Glycemic Control, Body Weight and Cardiovascular Risk Factors in Patients Enrolled in the Joslin Weight Achievement and Intensive Treatment (Why WAIT) Program: A Prospective Cohort Study
Status: Enrolling
Updated: 12/31/1969
Joslin Diabetes Center
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Schertz, TX
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Schertz, TX
Click here to add this to my saved trials
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sheffield, AL
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sheffield, AL
Click here to add this to my saved trials
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Spring Valley, CA
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Spring Valley, CA
Click here to add this to my saved trials
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fayetteville, NC
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fayetteville, NC
Click here to add this to my saved trials
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Hawaiian Gardens, CA
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Hawaiian Gardens, CA
Click here to add this to my saved trials
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Orlando, FL
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Blackfoot, ID
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Blackfoot, ID
Click here to add this to my saved trials
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Elgin, IL
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Elgin, IL
Click here to add this to my saved trials